Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)

被引：0
作者：
Drüeke T.B. [1 ,2 ]
机构：
[1] Inserm U-1018, Team 5, CESP, Versailles S.-Quentin-en-Yvelines Univ. (Paris-Ile-de-France-Ouest University, UVSQ, Paris-Sud University (UPS), and Paris Saclay University, Villejuif
[2] Inserm U-1018, Equipe 5, CESP, Hôpital Paul Brousse, 16 avenue Paul Vaillant Couturier, Villejuif Cedex
来源：
Renal Replacement Therapy | / 4卷 / 1期
关键词：
Chronic kidney disease; Dialysis; Erythropoietin; ESAs; Lessons; Randomized prospective trials;
D O I：
10.1186/s41100-018-0187-2
中图分类号：
学科分类号：
摘要：
Initially, the optimal degree of anemia correction in patients with chronic kidney disease by erythropoiesis-stimulating agents (ESAs) relied mainly on the results of observational studies. Many of these studies supported full anemia correction. Subsequently, randomized controlled trials of small sample size examined intermediate outcomes, but only trials with hard outcomes could settle this issue convincingly. In contrast to expectations based on epidemiological studies, the randomized controlled trials of large sample size performed in patients with chronic kidney disease in the last two decades have convincingly shown that full anemia correction, as compared to partial anemia correction, is associated with increased risk of adverse events and mortality and that the increased risk outweighs potential benefit. Although transfusion needs decrease and quality of life increases with actively raised hemoglobin levels in severely anemic patients with chronic kidney disease, any benefit of increasing hemoglobin levels above 11.5 g/dL is at best unclear at present. As some of these patients may experience improvement in physical and mental health and overall well-being above this level, individualization of therapy may be chosen in those who are prepared to accept the associated risks. Future, adequately powered, and blinded randomized controlled trials of anemia treatment using patient-reported outcomes as primary rather than secondary endpoints are needed to answer the question of the optimal hemoglobin target as regards the quality of life. © 2018 The Author(s).
引用
收藏
相关论文
共 60 条
[1]  
Moranne O., Froissart M., Rossert J., Gauci C., Boffa J.J., Haymann J.P., M'Rad M.B., Jacquot C., Houillier P., Stengel B., Et al., Timing of onset of CKD-related metabolic complications, J Am Soc Nephrol, 20, pp. 164-171, (2009)
[2]  
Hsu C.Y., McCulloch C.E., Curhan G.C., Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey, J Am Soc Nephrol, 13, pp. 504-510, (2002)
[3]  
Horl W.H., Anaemia management and mortality risk in chronic kidney disease, Nat Rev Nephrol, 9, pp. 291-301, (2013)
[4]  
KDIGO clinical practice guideline for anemia in chronic kidney disease, Kidney Int Suppl, 2, pp. 279-335, (2012)
[5]  
Li S., Foley R.N., Collins A.J., Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease, Int Urol Nephrol, 37, pp. 395-402, (2005)
[6]  
Bernhardt W.M., Wiesener M.S., Scigalla P., Chou J., Schmieder R.E., Gunzler V., Eckardt K.U., Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD, J Amer Soc Nephrol, 21, pp. 2151-2156, (2010)
[7]  
Fishbane S., Spinowitz B., Update on anemia in ESRD and earlier stages of CKD: Core Curriculum 2018, Am J Kidney Dis, 71, pp. 423-435, (2018)
[8]  
Macdougall I.C., Iron therapy for managing anaemia in chronic kidney disease, Curr Opin Nephrol Hypertens, 27, pp. 358-363, (2018)
[9]  
Nakanishi T., Hasuike Y., Otaki Y., Nanami M., Kuragano T., Dysregulated iron metabolism in patients on hemodialysis, Contrib Nephrol, 185, pp. 22-31, (2015)
[10]  
Eschbach J.W., Egrie J.C., Downing M.R., Browne J.K., Adamson J.W., Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase i and II clinical trial, N Engl J Med, 316, pp. 73-78, (1987)
123456